amifampridine has been researched along with Abnormal Movements in 1 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "2% of patients presented adverse drug reactions (ADRs) while using moderate doses of 3,4-DAP (20-30 mg daily or up to 80 mg daily for patients with LEMS) for periods of up to 51 months." | 2.75 | 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. ( Allain, H; Edan, G; Flet, L; Guillard, O; Javaudin, L; Leray, E; Polard, E, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flet, L | 1 |
| Polard, E | 1 |
| Guillard, O | 1 |
| Leray, E | 1 |
| Allain, H | 1 |
| Javaudin, L | 1 |
| Edan, G | 1 |
1 trial available for amifampridine and Abnormal Movements
| Article | Year |
|---|---|
3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Child; Cohort Studies; Dyskinesias; Fatigue | 2010 |